A Double-Blind, Randomised, Placebo-Controlled, Multicentre, Relapse-Prevention Study With Lu AA21004 in Patients With Generalized Anxiety Disorder.

Trial Profile

A Double-Blind, Randomised, Placebo-Controlled, Multicentre, Relapse-Prevention Study With Lu AA21004 in Patients With Generalized Anxiety Disorder.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Feb 2016

At a glance

  • Drugs Vortioxetine (Primary)
  • Indications Generalised anxiety disorder
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 03 Feb 2016 Results published in Lundbeck A/S media release.
    • 17 Oct 2012 Results presented at the 25th Annual Congress of the European College of Neuropsychopharmacology.
    • 03 Jul 2012 Planned number of patients changed from 300 to 600 as reported by EudraCT.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top